vs
Side-by-side financial comparison of FrontView REIT, Inc. (FVR) and Invivyd, Inc. (IVVD). Click either name above to swap in a different company.
Invivyd, Inc. is the larger business by last-quarter revenue ($17.2M vs $16.5M, roughly 1.0× FrontView REIT, Inc.). FrontView REIT, Inc. runs the higher net margin — -24.9% vs -64.3%, a 39.4% gap on every dollar of revenue.
Invivyd, Inc. is a clinical-stage biopharmaceutical company focused on developing broadly neutralizing antibody therapies to prevent and treat serious viral infectious diseases. Its core research and development pipeline targets high-burden respiratory pathogens including respiratory syncytial virus, catering to unmet medical needs of global patient groups.
FVR vs IVVD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.5M | $17.2M |
| Net Profit | $-4.1M | $-11.1M |
| Gross Margin | — | — |
| Operating Margin | — | -73.0% |
| Net Margin | -24.9% | -64.3% |
| Revenue YoY | — | 24.5% |
| Net Profit YoY | — | 40.0% |
| EPS (diluted) | $-0.19 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.5M | $17.2M | ||
| Q3 25 | $16.8M | $13.1M | ||
| Q2 25 | $17.6M | $11.8M | ||
| Q1 25 | $16.2M | $11.3M | ||
| Q4 24 | — | $13.8M | ||
| Q3 24 | $14.5M | $9.3M | ||
| Q2 24 | — | $2.3M | ||
| Q1 24 | — | $0 |
| Q4 25 | $-4.1M | $-11.1M | ||
| Q3 25 | $4.0M | $-10.5M | ||
| Q2 25 | $-2.9M | $-14.7M | ||
| Q1 25 | $-833.0K | $-16.3M | ||
| Q4 24 | — | $-18.4M | ||
| Q3 24 | $-2.4M | $-60.7M | ||
| Q2 24 | — | $-47.2M | ||
| Q1 24 | — | $-43.5M |
| Q4 25 | — | -73.0% | ||
| Q3 25 | — | -84.0% | ||
| Q2 25 | — | -127.8% | ||
| Q1 25 | — | -149.7% | ||
| Q4 24 | — | -139.1% | ||
| Q3 24 | — | -670.0% | ||
| Q2 24 | — | -2175.2% | ||
| Q1 24 | — | — |
| Q4 25 | -24.9% | -64.3% | ||
| Q3 25 | 23.9% | -79.7% | ||
| Q2 25 | -16.5% | -124.4% | ||
| Q1 25 | -5.1% | -144.1% | ||
| Q4 24 | — | -133.5% | ||
| Q3 24 | -16.7% | -653.1% | ||
| Q2 24 | — | -2086.9% | ||
| Q1 24 | — | — |
| Q4 25 | $-0.19 | $0.02 | ||
| Q3 25 | $0.19 | $-0.06 | ||
| Q2 25 | $-0.16 | $-0.12 | ||
| Q1 25 | $-0.06 | $-0.14 | ||
| Q4 24 | — | $-0.14 | ||
| Q3 24 | — | $-0.51 | ||
| Q2 24 | — | $-0.40 | ||
| Q1 24 | — | $-0.38 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $13.5M | $226.7M |
| Total DebtLower is stronger | $314.3M | — |
| Stockholders' EquityBook value | $391.2M | $241.5M |
| Total Assets | $854.4M | $276.9M |
| Debt / EquityLower = less leverage | 0.80× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.5M | $226.7M | ||
| Q3 25 | $19.6M | $85.0M | ||
| Q2 25 | $8.4M | $34.9M | ||
| Q1 25 | $3.3M | $48.1M | ||
| Q4 24 | — | $69.3M | ||
| Q3 24 | — | $106.9M | ||
| Q2 24 | — | $147.9M | ||
| Q1 24 | — | $189.4M |
| Q4 25 | $314.3M | — | ||
| Q3 25 | $307.1M | — | ||
| Q2 25 | $316.9M | — | ||
| Q1 25 | $310.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $391.2M | $241.5M | ||
| Q3 25 | $385.2M | $93.1M | ||
| Q2 25 | $369.9M | $42.8M | ||
| Q1 25 | $324.7M | $54.1M | ||
| Q4 24 | — | $67.5M | ||
| Q3 24 | $1.0K | $83.2M | ||
| Q2 24 | — | $140.6M | ||
| Q1 24 | — | $178.5M |
| Q4 25 | $854.4M | $276.9M | ||
| Q3 25 | $846.8M | $139.2M | ||
| Q2 25 | $856.5M | $89.1M | ||
| Q1 25 | $860.8M | $103.7M | ||
| Q4 24 | — | $129.5M | ||
| Q3 24 | $1.0K | $161.9M | ||
| Q2 24 | — | $177.3M | ||
| Q1 24 | — | $215.5M |
| Q4 25 | 0.80× | — | ||
| Q3 25 | 0.80× | — | ||
| Q2 25 | 0.86× | — | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $42.1M | $-15.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $42.1M | $-15.5M | ||
| Q3 25 | $8.3M | $-8.3M | ||
| Q2 25 | $9.3M | $-13.3M | ||
| Q1 25 | $8.1M | $-21.1M | ||
| Q4 24 | — | $-37.6M | ||
| Q3 24 | — | $-41.1M | ||
| Q2 24 | — | $-41.6M | ||
| Q1 24 | — | $-50.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-13.3M | ||
| Q1 25 | — | $-21.3M | ||
| Q4 24 | — | $-37.6M | ||
| Q3 24 | — | $-41.1M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-50.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -112.9% | ||
| Q1 25 | — | -188.2% | ||
| Q4 24 | — | -272.2% | ||
| Q3 24 | — | -441.6% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 2.06× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
